PSTV Plus Therapeutics Inc
17,990
$2.16
$0.08
(3.57%)
| Watchers | 17,990 |
| 52-Wk Low | $0.9694 |
| 52-Wk High | $4.45 |
| Market Cap | $9.24M |
| Volume | 65,498.00 |
| 52-Wk High | $4.45 |
| 52-Wk Low | $0.9694 |
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseBenzinga • 19 days ago
Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.
read more...
Share to Feed
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an...
Plus Therapeutics (PSTV Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from...
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE...
Plus Therapeutics (PSTV Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached...
AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company ), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...